Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
$13.01
$21.36
$11.36
▼
$35.83
$672.92M1.661.43 million shs616,141 shs
CG Oncology, Inc. stock logo
CGON
CG Oncology
$74.40
$68.04
$37.01
▼
$80.97
$6.65B0.351.21 million shs3.31 million shs
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$285.78
+0.0%
$266.97
$193.55
▼
$288.11
$687.95B0.227.46 million shs6.28 million shs
Upstream Bio, Inc. stock logo
UPB
Upstream Bio
$2.78
$4.24
$2.68
▼
$33.68
$152.37M1.611.30 million shs891,335 shs
Upstream Bio, Inc. stock logo
UPB
Upstream Bio
$2.78
$4.24
$2.68
▼
$33.68
$152.37M1.611.30 million shs891,335 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
0.00%-4.62%-21.91%-55.15%-37.12%
CG Oncology, Inc. stock logo
CGON
CG Oncology
0.00%-2.09%+24.31%-3.51%+81.42%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.00%+3.49%+11.83%+8.90%+45.80%
Upstream Bio, Inc. stock logo
UPB
Upstream Bio
0.00%-13.93%+0.72%-61.06%-88.67%
Upstream Bio, Inc. stock logo
UPB
Upstream Bio
0.00%-13.93%+0.72%-61.06%-88.67%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
$13.01
$21.36
$11.36
▼
$35.83
$672.92M1.661.43 million shs616,141 shs
CG Oncology, Inc. stock logo
CGON
CG Oncology
$74.40
$68.04
$37.01
▼
$80.97
$6.65B0.351.21 million shs3.31 million shs
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$285.78
+0.0%
$266.97
$193.55
▼
$288.11
$687.95B0.227.46 million shs6.28 million shs
Upstream Bio, Inc. stock logo
UPB
Upstream Bio
$2.78
$4.24
$2.68
▼
$33.68
$152.37M1.611.30 million shs891,335 shs
Upstream Bio, Inc. stock logo
UPB
Upstream Bio
$2.78
$4.24
$2.68
▼
$33.68
$152.37M1.611.30 million shs891,335 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
0.00%-4.62%-21.91%-55.15%-37.12%
CG Oncology, Inc. stock logo
CGON
CG Oncology
0.00%-2.09%+24.31%-3.51%+81.42%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.00%+3.49%+11.83%+8.90%+45.80%
Upstream Bio, Inc. stock logo
UPB
Upstream Bio
0.00%-13.93%+0.72%-61.06%-88.67%
Upstream Bio, Inc. stock logo
UPB
Upstream Bio
0.00%-13.93%+0.72%-61.06%-88.67%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
2.73
Moderate Buy$24.8991.31% Upside
CG Oncology, Inc. stock logo
CGON
CG Oncology
2.73
Moderate Buy$88.1118.43% Upside
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
2.73
Moderate Buy$275.92-3.45% Downside
Upstream Bio, Inc. stock logo
UPB
Upstream Bio
2.43
Hold$26.67859.23% Upside
Upstream Bio, Inc. stock logo
UPB
Upstream Bio
2.43
Hold$26.67859.23% Upside

Current Analyst Ratings Breakdown

Latest UPB, CGON, AVBP, JNJ, and UPB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/13/2026
Upstream Bio, Inc. stock logo
UPB
Upstream Bio
Reiterated RatingSell (D-)
11/13/2026
Upstream Bio, Inc. stock logo
UPB
Upstream Bio
Reiterated RatingSell (D-)
11/12/2026
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
Reiterated RatingOverweight
11/11/2026
Upstream Bio, Inc. stock logo
UPB
Upstream Bio
Lower Price TargetBuy$18.00
11/11/2026
Upstream Bio, Inc. stock logo
UPB
Upstream Bio
Lower Price TargetBuy$18.00
11/10/2026
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
Boost Price TargetBuy$21.00 ➝ $24.00
11/9/2026
CG Oncology, Inc. stock logo
CGON
CG Oncology
Lower Price TargetBuy$90.00 ➝ $89.00
11/6/2026
CG Oncology, Inc. stock logo
CGON
CG Oncology
Boost Price TargetOutperform$80.00 ➝ $84.00
10/27/2026
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
Boost Price TargetBuy$18.00 ➝ $30.00
10/26/2026
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
Set Price Target$21.00
10/26/2026
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
Reiterated RatingOutperform$25.00
(Data available from 11/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
N/AN/AN/AN/A$7.44 per shareN/A
CG Oncology, Inc. stock logo
CGON
CG Oncology
$6.17M1,077.74N/AN/A$9.33 per share7.97
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$94.19B7.30$14.12 per share20.24$33.85 per share8.44
Upstream Bio, Inc. stock logo
UPB
Upstream Bio
$2.85M53.46N/AN/A$6.29 per share0.44
Upstream Bio, Inc. stock logo
UPB
Upstream Bio
$2.85M53.46N/AN/A$6.29 per share0.44
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
-$166.31M-$3.60N/AN/AN/AN/A-48.60%-45.26%N/A
CG Oncology, Inc. stock logo
CGON
CG Oncology
-$160.99M-$2.76N/AN/AN/A-3,851.09%-24.58%-23.40%N/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$26.80B$6.6043.3024.722.8216.20%31.64%13.04%1/26/2027 (Estimated)
Upstream Bio, Inc. stock logo
UPB
Upstream Bio
-$143.44M-$3.02N/AN/AN/A-5,712.33%-57.09%-54.69%N/A
Upstream Bio, Inc. stock logo
UPB
Upstream Bio
-$143.44M-$3.02N/AN/AN/A-5,712.33%-57.09%-54.69%N/A

Latest UPB, CGON, AVBP, JNJ, and UPB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/10/2026Q3 2026
Upstream Bio, Inc. stock logo
UPB
Upstream Bio
-$0.7314-$0.7520-$0.0206-$0.75$0.55 million$0.40 million
11/10/2026Q3 2026
Upstream Bio, Inc. stock logo
UPB
Upstream Bio
-$0.7314-$0.7520-$0.0206-$0.75$0.55 million$0.40 million
11/9/2026Q3 2026
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
-$1.05-$0.81+$0.24-$0.81$0.80 million$5.00 million
11/6/2026Q3 2026
CG Oncology, Inc. stock logo
CGON
CG Oncology
-$0.8341-$0.64+$0.1941-$0.64$0.55 million$1.60 million
10/13/2026Q3 2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.53$2.59+$0.06$0.09$25.38 billion$25.40 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
N/AN/AN/AN/AN/A
CG Oncology, Inc. stock logo
CGON
CG Oncology
N/AN/AN/AN/AN/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$5.361.88%+5.25%81.21%64 Years
Upstream Bio, Inc. stock logo
UPB
Upstream Bio
N/AN/AN/AN/AN/A
Upstream Bio, Inc. stock logo
UPB
Upstream Bio
N/AN/AN/AN/AN/A

Latest UPB, CGON, AVBP, JNJ, and UPB Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/13/2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
quarterly$1.342.15%11/24/202611/24/202612/8/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
N/A
17.64
17.64
CG Oncology, Inc. stock logo
CGON
CG Oncology
N/A
21.70
21.68
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.44
1.02
0.74
Upstream Bio, Inc. stock logo
UPB
Upstream Bio
N/A
20.45
20.45
Upstream Bio, Inc. stock logo
UPB
Upstream Bio
N/A
20.45
20.45

Institutional Ownership

CompanyInstitutional Ownership
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
9.48%
CG Oncology, Inc. stock logo
CGON
CG Oncology
26.56%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
69.55%
Upstream Bio, Inc. stock logo
UPB
Upstream Bio
N/A
Upstream Bio, Inc. stock logo
UPB
Upstream Bio
N/A

Insider Ownership

CompanyInsider Ownership
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
8.58%
CG Oncology, Inc. stock logo
CGON
CG Oncology
4.80%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.16%
Upstream Bio, Inc. stock logo
UPB
Upstream Bio
16.46%
Upstream Bio, Inc. stock logo
UPB
Upstream Bio
16.46%
CompanyEmployeesShares OutstandingFree FloatOptionable
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
7751.72 million47.29 millionOptionable
CG Oncology, Inc. stock logo
CGON
CG Oncology
14289.32 million85.03 millionOptionable
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
138,2002.41 billion2.40 billionOptionable
Upstream Bio, Inc. stock logo
UPB
Upstream Bio
7554.81 million45.79 millionOptionable
Upstream Bio, Inc. stock logo
UPB
Upstream Bio
7554.81 million45.79 millionOptionable

Recent News About These Companies

HC Wainwright Increases Earnings Estimates for Upstream Bio
Upstream Bio (NASDAQ:UPB) Stock Gets Price Target Reduction from HC Wainwright
HC Wainwright Raises Earnings Estimates for Upstream Bio
Upstream Bio, Inc. (UPB) - What Are Researchers Saying About This Stock?
Upstream Bio Outlines Phase 3 Plans for Verekitug
Upstream Bio Inc (UPB)

New MarketBeat Followers Over Time

Media Sentiment Over Time

ArriVent BioPharma stock logo

ArriVent BioPharma NASDAQ:AVBP

$13.01 0.00 (0.00%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$13.22 +0.21 (+1.61%)
As of 07:04 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

CG Oncology stock logo

CG Oncology NASDAQ:CGON

$74.40 0.00 (0.00%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$73.44 -0.97 (-1.30%)
As of 07:32 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

Johnson & Johnson stock logo

Johnson & Johnson NYSE:JNJ

$285.78 +0.03 (+0.01%)
Closing price 11/13/2026 03:59 PM Eastern
Extended Trading
$290.21 +4.43 (+1.55%)
As of 07:36 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Upstream Bio stock logo

Upstream Bio NASDAQ:UPB

$2.78 0.00 (0.00%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$2.78 0.00 (-0.18%)
As of 07:29 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.

Upstream Bio stock logo

Upstream Bio NASDAQ:UPB

$2.78 0.00 (0.00%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$2.78 0.00 (-0.18%)
As of 07:29 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.